Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors

Mohamad Jawhar, MD, Juliana Schwaab, MD, Manja Meggendorfer, PhD, Nicole Naumann, Hans-Peter Horny, MD, Karl Sotlar, MD, Torsten Haferlach, MD, Karla Schmitt, MD, Alice Fabarius, PhD, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD, Andreas Reiter, MD

Blood (2016) 128 (22): 3109.

https://doi.org/10.1182/blood.V128.22.3109.3109

Published: 2016

Journal Articles

Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis

Mohamad Jawhar, MD, Juliana Schwaab, MD, Nicole Naumann, Sebastian Kluger, Hans-Peter Horny, MD, Karl Sotlar, MD, Torsten Haferlach, MD, Georgia Metzgeroth, MD, Alice Fabarius, PhD, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Manja Meggendorfer, PhD, Andreas Reiter, MD

Blood (2016) 128 (22): 945.

https://doi.org/10.1182/blood.V128.22.945.945

Published: 2016

Journal Articles

Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis

Nicole Naumann, Mohamad Jawhar, MD, Juliana Schwaab, MD, Georgia Metzgeroth, MD, Henning D Popp, MD, Nada Khaled, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Peter Valent, MD, Claudia Haferlach, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, Prof, MD, Manja Meggendorfer, PhD, Nicholas C.P. Cross, PhD, Wolf-Karsten Hofmann, MD, Andreas Reiter, MD, Alice Fabarius, PhD

Blood (2016) 128 (22): 947.

https://doi.org/10.1182/blood.V128.22.947.947

Published: 2016

Journal Articles

Correlation of CD30 Expression on Neoplastic Mast Cells in Systemic Mastocytosis Assessed By Immunohistochemistry Versus Multiparameter Flow Cytometry and Correlation to Clinical Parameters

Frauke Bellos, MD, Karl Sotlar, MD, Susanne Schnittger, PhD, Claudia Haferlach, MD, Torsten Haferlach, Wolfgang Kern, MD

Blood (2015) 126 (23): 1616.

https://doi.org/10.1182/blood.V126.23.1616.1616

Published: 2015

Journal Articles

Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V + Advanced Systemic Mastocytosis

Mohamad Jawhar, Juliana Schwaab, MD, Susanne Schnittger, PhD, Manja Meggendorfer, PhD, Karl Sotlar, MD, Hans-Peter Horny, MD, Georgia Metzgeroth, MD, Sebastian Kluger, Nicole Naumann, Claudia Haferlach, MD, Torsten Haferlach, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Alice Charlotte Fabarius, PhD, Nicholas C.P. Cross, PhD, Andreas Reiter, MD

Blood (2015) 126 (23): 349.

https://doi.org/10.1182/blood.V126.23.349.349

Published: 2015

Journal Articles

Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event

Mohamad Jawhar, MD, Juliana Schwaab, MD, Susanne Schnittger, PhD, Karl Sotlar, MD, Hans Peter Horny, MD, Georgia Metzgeroth, Sven Schneider, MD, Nadine Müller, Nicole Naumann, Christoph Walz, MD, Torsten Haferlach, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Alice Fabarius, PhD, Andreas Reiter, MD

Blood (2014) 124 (21): 3216.

https://doi.org/10.1182/blood.V124.21.3216.3216

Published: 2014

Journal Articles

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Jason Gotlib, MD MS, Hanneke C. Kluin-Nelemans, MD PhD, Tracy I. George, MD, Cem Akin, MD PhD, Karl Sotlar, MD, Olivier Hermine, MD PhD, Farrukh Awan, MD MS, Elizabeth O Hexner, MD, Michael Mauro, MD, David Sternberg, MD PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Eric Stanek, PharmD, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2014) 124 (21): 636.

https://doi.org/10.1182/blood.V124.21.636.636

Published: 2014

Journal Articles

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Jason Gotlib, MD, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, John Coombs, PharmD, MBA, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2013) 122 (21): 106.

https://doi.org/10.1182/blood.V122.21.106.106

Published: 2013

Journal Articles

Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis

Blood (2013) 122 (21): 4094.

https://doi.org/10.1182/blood.V122.21.4094.4094

Published: 2013

Journal Articles

The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype.

Juliana Schwaab, MD, Philipp Erben, MD, Hans-Peter Horny, MD, Martina Teichmann, MD, Georgia Metzgeroth, MD, Thomas Ernst, MD, Karl Sotlar, MD, Martin C Mueller, MD, Alexander Marx, MD, Karin Hartmann, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD, Wolf Karsten Hofmann, MD, PhD, Andreas Reiter, MD

Blood (2012) 120 (21): 2859.

https://doi.org/10.1182/blood.V120.21.2859.2859

Published: 2012

Journal Articles

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Jason Gotlib, MD, MS, Hanneke C. Kluin-Nelemans, MD, PhD, Tracy I. George, MD, Cem Akin, MD, PhD, Karl Sotlar, MD, Olivier Hermine, MD, PhD, Farrukh Awan, MD, MS, Elizabeth Hexner, MD, Michael J. Mauro, MD, Rodica Morariu, MD, Margaret Squier, MD, PhD, Matthieu Villeneuve, Fabienne Emery-Salbert, MSc, Karin Hartmann, MD, Hans-Peter Horny, MD, Peter Valent, MD, Andreas Reiter, MD

Blood (2012) 120 (21): 799.

https://doi.org/10.1182/blood.V120.21.799.799

Published: 2012

Journal Articles

Does Microangiopathy Predict Chronic GvHD After Allogeneic Stem Cell Transplantation? A Clinical and Immunohistochemical Study on Bone Marrow Biopsies

Wolfgang Hill, MD, Karl Sotlar, MD, Hans Jochem Kolb, MD, Andreas Hausmann, MD, Johanna Tischer, MD, Andreas Rank, MD

Blood (2011) 118 (21): 4540.

https://doi.org/10.1182/blood.V118.21.4540.4540

Published: 2011

Journal Articles

The Target Receptor Siglec-3 (CD33) Is Expressed on AML Stem Cells in a Majority of All Patients with AML.

Alexander W. Hauswirth, MD, Stefan FLorian, MD, Maria-Theresa Krauth, MD, Gerit-Holger Schernthaner, MD, Edgar Selzer, MD, Volker Wacheck, MD, Dieter Printz, Gerhard Fritsch, MD, Karl Sotlar, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2005) 106 (11): 4324.

https://doi.org/10.1182/blood.V106.11.4324.4324

Published: 2005

Journal Articles

c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.

Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Stefan Florian, Maria-Theresa Krauth, MD, Martin Bilban, PhD, Harald Esterbauer, MD, PhD, Oswald Wagner, MD, Reinhard Kodym, MD, Karl Sotlar, MD, Jack B. Longley, MD, Hans-Peter Horny, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2004) 104 (11): 485.

https://doi.org/10.1182/blood.V104.11.485.485

Published: 2004

NARROW

Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors

Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis

Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis

Correlation of CD30 Expression on Neoplastic Mast Cells in Systemic Mastocytosis Assessed By Immunohistochemistry Versus Multiparameter Flow Cytometry and Correlation to Clinical Parameters

Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V + Advanced Systemic Mastocytosis

Molecular Profiling of Myeloid Progenitor Cells in Multi-Mutated Advanced Systemic Mastocytosis Identifies KIT D816V As a Distinct and Late Event

Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial

Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial

Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis

The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype.

KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial

Does Microangiopathy Predict Chronic GvHD After Allogeneic Stem Cell Transplantation? A Clinical and Immunohistochemical Study on Bone Marrow Biopsies

The Target Receptor Siglec-3 (CD33) Is Expressed on AML Stem Cells in a Majority of All Patients with AML.

c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only